In vivo release of anti-Xa clotting activity by a heparin analogue.
D000328:Adult; D000925:Anticoagulants / Q000494:pharmacology*; D000937:Antigen-Antibody Reactions; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D001798:Blood Proteins / Q000276:immunology; D002807:Chondroitin / Q000031:analogs & derivatives*; D002809:Chondroitin Sulfates / Q000494:pharmacology*; D005170:Factor X / Q000378:metabolism; D005260:Female; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D008071:Lipoprotein Lipase / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011479:Protamines / Q000494:pharmacology
D000925:Anticoagulants; D001798:Blood Proteins; D011479:Protamines; C026210:SSHA; D005170:Factor X; D006493:Heparin; D002807:Chondroitin; D002809:Chondroitin Sulfates; D008071:Lipoprotein Lipase